Liposome-based approaches to overcome anticancer drug resistance

Drug Resistance Updates

Volumn 6, Issue 5, 2003, Pages 271-279

  Mamot, Christoph ^a   Drummond, Daryl C ^b,c   Hong, Keelung ^c   Kirpotin, Dmitri B ^b,c   Park, John W ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^c Hermes Biosciences Inc   (United States)

Author keywords

Drug delivery; Immunoliposomes; Liposomes; MDR; Multidrug resistance

Indexed keywords

ANNAMYCIN; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CARMUSTINE; CYCLOSPORIN; DAUNORUBICIN; DOXORUBICIN; GLYCOPROTEIN P; IMMUNOLIPOSOME; LIPOSOME; METHOTREXATE; NAVELBINE; PACLITAXEL; PLATINUM DERIVATIVE; TRASTUZUMAB; VALSPODAR; VINCRISTINE;

CANCER; CANCER CELL; CANCER RESISTANCE; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG RELEASE; DRUG SAFETY; DRUG TARGETING; GENE THERAPY; GLIOBLASTOMA; HUMAN; INTERNALIZATION; KAPOSI SARCOMA; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; REVIEW; TOXICITY;

EID: 0344738659     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1368-7646(03)00082-7     Document Type: Article

References (76)

1. Abe, T., Hasegawa, S., Taniguchi, K., Yokomizo, A., Kuwano, T., Ono, M., Mori, T., Hori, S., Kohno, K., Kuwano, M., 1994. Possible involvement of multidrug-resistance-associated protein (MRP) gene expression in spontaneous drug resistance to vincristine, etoposide and adriamycin in human glioma cells. Int. J. Cancer 58, 860-864.
2. Advani, R., Fisher, G.A., Lum, B.L., Hausdorff. J., Halsey, J., Litchman, M., Sikic, B.I., 2001. A phase I trial of doxorubicin, paclitaxel, and valspodar (PSC 833), a modulator of multidrug resistance. Clin. Cancer Res. 7, 1221-1229.
3. Aksentijevich, I., Pastan, I., Lunardi-Iskandar, Y., Gallo, R.C., Gottesman, M.M., Thierry, A.R., 1996. In vitro and in vivo liposome-mediated gene transfer leads to human MDR1 expression in mouse bone marrow progenitor cells. Hum. Gene Ther. 7, 1111-1122.
4. Alahari, S.K., Dean, N.M., Fisher, M.H., Delong, R., Manoharan, M., Tivel, K.L., Juliano, R.L., 1996. Inhibition of expression of the multi-drug resistance-associated P-glycoprotein of by phosphorothioate and 5′ cholesterol-conjugated phosphorothioate antisense oligonucleotides. Mol. Pharmacol. 50, 808-819.
5. Aviles, A., Neri, N., Castaneda, C., Talavera, A., Huerta-Guzman, J., Gonzalez, M., 2002. Pegylated liposomal doxorubicin in combination chemotherapy in the treatment of previously untreated aggressive diffuse large B-cell lymphoma. Med. Oncol. 19, 55-58.
6. Batist, G., Barton, J., Chaikin, P., Swenson, C., Welles, L., 2002. Myocet (liposome-encapsulated doxorubicin citrate): a new approach in breast cancer therapy. Expert Opin. Pharmacother. 12, 1739-1751.
7. Baudard. M., Flotte, T.R., Aran, J.M., Thierry, A.R., Pastan, I., Pang, M.G., Kearns, W.G., Gottesman, M.M., 1996. Expression of the human multidrug resistance and glucocerebrosidase cDNAs from adeno-associated vectors: efficient promoter activity of AAV sequences and in vivo delivery via liposomes. Hum. Gene Ther. 7, 1309-1322.
8. Booser, D.J., Esteva, F.J., Rivera, E., Valero, V., Esparza-Guerra, L., Priebe, W., Hortobagyi, G.N., 2002. Phase II study of liposomal annamycin in the treatment of doxorubicin-resistant breast cancer. Cancer Chemother. Pharmacol. 50, 6-8.
9. Bosch, I., Dunussi-Joannopoulos, K., Wu, R.L., Furlong, S.T., Croop, J., 1997. Phosphatidylcholine and phosphatidylethanolamine behave as substrates of the human MDR1 P-glycoprotein. Biochemistry 36, 5685-5694.
10. Broxterman, H.J., Lankelma, J., Hoekman, K., 2003. Resistance to cytotoxic and anti-angiogenic agents: similarities and differences. Drug Resist. Update 6, 111-127.
11. Burke, T.G., Bom, D., 2000. Camptothecin design and delivery approaches for elevating anti-topoisomerase I activities in vivo. Ann. N.Y. Acad. Sci. 922, 36-45.
12. Cole, S.P., Deeley, R.G., 1998. Multidrug resistance mediated by the ATP-binding cassette transporter protein MRP. Bioessays 20, 931-940.
13. Cunningham, J., Oiwa, Y., Nagy, D., Podsakoff, G., Colosi, P., Bankiewicz, K.S., 2000. Distribution of AAV-TK following intracranial convection-enhanced delivery into rats. Cell Transplant 9, 585-594.
14. Daoud, S.S., Juliano, R.L., 1986. Reduced toxicity and enhanced antitumor effects in mice of the ionophoric drug valinomycin when incorporated in liposomes. Cancer Res. 46, 5518-5523.
15. Daoud, S.S., Juliano, R.L., 1989. Modulation of doxorubicin resistance by valinomycin (NSC 122023) and liposomal valinomycin in Chinese hamster ovary cells. Cancer Res. 49, 2661-2667.
16. Drummond, D.C., Meyer, O., Hong, K., Kirpotin, D.B., Papahadjopoulos, D., 1999. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol. Rev. 51, 691-743.
17. Drummond, D.C., Zignani, M., Leroux, J., 2000. Current status of pH-sensitive liposomes in drug delivery. Prog. Lipid Res. 39, 409-460.
18. Fan, D., Bucana, C.D., O'Brian, C.A., Zwelling, L.A., Seid, C., Fidler, I.J., 1990. Enhancement of murine tumor cell sensitivity to adriamycin by presentation of the drug in phosphatidylcholine- phosphatidylserine liposomes. Cancer Res. 50, 3619-3626.
19. Forssen, E.A., Coulter, D.M., Proffitt, R.T., 1992. Selective in vivo localization of daunorubicin small unilamellar vesicles in solid tumors. Cancer Res. 52, 3255-3261.
20. Gordon, A.N., Fleagle, J.T., Guthrie, D., Parkin, D.E., Gore, M.E., Lacave, A.J., 2001. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J. Clin. Oncol. 19, 3312-3322.
21. Goren, D., Horowitz, A.T., Tzemach, D., Tarshish, M., Zalipsky, S., Gabizon, A., 2000. Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump. Clin. Cancer Res. 6, 1949-1957.
22. Greiser, U., Drummond, D.C., Mamot, C., et al., 2002. Targeting immunoliposomes to endothelial receptors. Proc. Am. Assoc. Cancer Res. 43, 410 (Abstract).
23. Huang, S.K., Lee, K.D., Hong, K., Friend, D.S., Papahadjopoulos, D., 1992. Microscopic localization of sterically stabilized liposomes in colon carcinoma-bearing mice. Cancer Res. 52, 5135-5143.
24. Hughes, C.S., Vaden, S.L., Manaugh, C.A., Price, G.S., Hudson, L.C., 1998. Modulation of doxorubicin concentration by cyclosporin A in brain and testicular barrier tissues expressing P-glycoprotein in rats. J. Neurooncol. 37, 45-54.
25. Huwyler, J., Cerletti, A., Fricker, G., Eberle, A.N., Drewe, J., 2002. By-passing of P-glycoprotein using immunoliposomes. J. Drug Target. 10, 73-79.
26. Juranka, P.F., Zastawny, R.L., Ling, V., 1989. P-glycoprotein: multidrug-resistance and a superfamily of membrane-associated transport proteins. FASEB J. 3, 2583-2592.
27. Kang, M.H., Figg, W.D., Ando, Y., Blagosklonny, M.V., Liewehr, D., Fojo, T., Bates, S.E., 2001. The P-glycoprotein antagonist PSC 833 increases the plasma concentrations of 6alpha-hydroxypaclitaxel, a major metabolite of paclitaxel. Clin. Cancer Res. 7, 1610-1617.
28. Kellen, J.A., 1994. The phenomenon of multidrug resistance. In: Kellen, J.A. (Ed.), Reversal of Multidrug Resistance in Cancer. CRC Press, Boca Raton, FL, pp. 1-21.
29. Kirpotin, D.B., Hong, K., Mullah, N., Papahadjopoulos, D., Zalipsky, S., 1996. Liposomes with detachable polymer coating: destabilization and fusion of dioleoylphosphatidyl-ethanolamine vesicles triggered by cleavage of surface-grafted poly(ethylene glycol). FEBS Lett. 388, 115-118.
30. Kirpotin, D.B., Park, J.W., Hong, K., Zalipsky, S., Li, W.L., Carter, P., Benz, C.C., Papahadjopoulos, D., 1997. Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro. Biochemistry 36, 66-75.
31. Kobayashi, H., Takemura, Y., Miyachi, H., 2001. Novel approaches to reversing anti-cancer drug resistance using gene-specific therapeutics. Hum. Cell 14, 172-184.
32. Koukourakis, M.I., Koukouraki, S., Fezoulidis, I., et al., 2000. High intratumoural accumulation of stealth liposomal doxorubicin (Caelyx) in glioblastomas and in metastatic brain tumours. Br. J. Cancer 83, 1281-1286.
33. Krishna, R., Mayer, L.D., 1997. Liposomal doxorubicin circumvents PSC 833-free drug interactions, resulting in effective therapy of multidrug-resistant solid tumors. Cancer Res. 57, 5246-5253.
34. Krishna, R., McIntosh, N., Riggs, K.W., Mayer, L.D., 1999. Doxorubicin encapsulated in sterically stabilized liposomes exhibits renal and biliary clearance properties that are independent of valspodar (PSC 833) under conditions that significantly inhibit non-encapsulated drug excretion. Clin. Cancer Res. 5, 2939-2947.
35. Lee, K.D., Hong, K., Papahadjopoulos, D., 1992. Recognition of liposomes by cells: in vitro binding and endocytosis mediated by specific lipid headgroups and surface charge density. Biochim. Biophys. Acta 1103, 185-197.
36. Lee, C.G., Vieira, W.D., Pastan, I., Gottesman, M.M., 2001. An episomally maintained MDR1 gene for gene therapy. Hum. Gene Ther. 12, 945-953.
37. Leonard, G.D., Polgar, O., Bates, S.E., 2002. ABC transporters and inhibitors: new targets, new agents. Curr. Opin. Investig. Drugs 3, 1652-1659.
38. Lo, Y.L., 2000. Phospholipids as multidrug resistance modulators of the transport of epirubicin in human intestinal epithelial Caco-2 cell layers and everted gut sacs of rats. Biochem. Pharmacol. 60, 1381-1390.
39. Lonser, R.R., Walbridge, S., Garmestani, K., et al., 2002. Successful and safe perfusion of the primate brainstem: in vivo magnetic resonance imaging of macromolecular distribution during infusion. J. Neurosurg. 97, 905-913.
40. Lu, Y., Low, P.S., 2002. Folate-mediated delivery of macromolecular anticancer therapeutic agents. Adv. Drug Deliv. Rev. 54, 675-693.
41. Mamot, C., Bankiewicz, K.S., Hadaczek, P., Drummond, D.C., Guo, Z., Hong, K., Kirpotin, D.B., Marks, J.D., Berger, M., Park, J.W., 2003a. Immunoliposomes target EGFR-overexpressing brain and other tumors for efficient drug delivery and enhanced efficacy. Proc. Am. Soc. Clin. Oncol. 22, 206 (Abstract).
42. Mamot, C., Drummond, D.C., Greiser, U., Hong, K., Kirpotin, D.B., Marks, J.D., Park, J.W., 2003b. Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells. Cancer Res. 63, 3154-3161.
43. Massing, U., Fuxius, S., 2000. Liposomal formulations of anticancer drugs: selectivity and effectiveness. Drug Resist. Update 3, 171-177.
44. Masuda, Y., Kobayashi, H., Holland, J.F., Ohnuma, T., 1998. Reversal of multidrug resistance by a liposome-MDR1 ribozyme complex. Cancer Chemother. Pharmacol. 42, 9-16.
45. Matsumura, Y., Maeda, H., 1986. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 46, 6387-6392.
46. Matsuo, H., Wakasugi, M., Takanaga, H., Ohtani, H., Naito, M., Tsuruo, T., Sawada, Y., 2001. Possibility of the reversal of multidrug resistance and the avoidance of side effects by liposomes modified with MRK-16, a monoclonal antibody to P-glycoprotein. J. Control. Release 77, 77-86.
47. Matteucci, M.L., Anyarambhatla, G., Rosner, G., Azuma, C., Fisher, P.E., Dewhirst, M.W., Needham, D., Thrall, D.E., 2000. Hyperthermia increases accumulation of technetium-99m-labeled liposomes in feline sarcomas. Clin. Cancer Res. 6, 3748-3755.
48. Merlin, J.L., Marchal, S., Ramacci, C., Notter, D., Vigneron, C., 1993. Antiproliferative activity of thermosensitive liposome-encapsulated doxorubicin combined with 43 degrees C hyperthermia in sensitive and multidrug-resistant MCF-7 cells. Eur. J. Cancer 29A, 2264-2268.
49. Michieli, M., Damiani, D., Ermacora, A., et al., 1999. Liposome-encapsulated daunorubicin for PGP-related multidrug resistance. Br. J. Haematol. 106, 92-99.
50. Mohrbacher, A.F., Gregory, S.A., Gabriel, D.A., Rusk, J.M., Giles, F.J., 2002. Liposomal daunorubicin (DaunoXome) plus dexamethasone for patients with multiple myeloma. A phase II International Oncology Study Group study. Cancer 94, 2645-2652.
51. Needham, D., Anyarambhatla, G., Kong, G., Dewhirst, M.W., 2000. A new temperature-sensitive liposome for use with mild hyperthermia: characterization and testing in a human tumor xenograft model. Cancer Res. 60, 1197-1201.
52. Northfelt, D.W., Dezube, B.J., Thommes, J.A., et al., 1997. Efficacy of pegylated-liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma after failure of standard chemotherapy. J. Clin. Oncol. 15, 653-659.
53. Oudard, S., Thierry, A., Jorgensen, T.J., Rahman, A., 1991. Sensitization of multidrug-resistant colon cancer cells to doxorubicin encapsulated in liposomes. Cancer Chemother. Pharmacol. 28, 259-265.
54. Park, J.W., 2002. Liposome-based drug delivery in breast cancer treatment. Breast Cancer Res. 4, 95-99.
55. Park, J.W., Hong, K., Carter, P., et al., 1995. Development of anti-p185HER2 immunoliposomes for cancer therapy. Proc. Natl. Acad. Sci. U.S.A. 92, 1327-1331.
56. Park, J.W., Hong, K., Kirpotin, D.B., Papahadjopoulos, D., Benz, C.C., 1997. Immunoliposomes for cancer treatment. Adv. Pharmacol. 40, 399-435.
57. Park, J.W., Stauffer, P., Diederich, C., Colbern, G., Lozner, A., Kirpotin, D.B., Rugo, H., Valente, N., Sneed, P., 2001. Hyperthermia (HT) + Doxil significantly enhances drug delivery and efficacy in metastatic breat cancer of the chest wall (CW): a phase I/II study. Proc. Am. Soc. Clin. Oncol. 20, 47a (Abstract).
58. Park, J.W., Hong, K., Kirpotin, D.B., et al., 2002. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin. Cancer Res. 8, 1172-1181.
59. Pedroso de Lima, M.C., Neves, S., Filipe, A., Duzgunes, N., Simoes, S., 2003. Cationic liposomes for gene delivery: from biophysics to biological applications. Curr. Med. Chem. 10, 1221-1231.
60. Perez-Soler, R., Yang, L.Y., Drewinko, B., Lauterzstain, J., Khokhar, A.R., 1988. Increased cytotoxicity and reversal of resistance to cis-diammine-dichloro-platinum(II) with entrapment of cis-bis-neodecanoatotrans-R,R-1,2-diaminocyclohexaneplatinum(II) in multilamellar lipid vesicles. Cancer Res. 48, 4509-4512.
61. Poste, G., Papahadjopoulos, D., 1976. Drug-containing lipid vesicles render drug-resistant cell sensitive to actinomycin D. Nature 261, 699-701.
62. Renes, J., de Vries, E.G., Jansen, P.L., Muller, M., 2000. The (patho)physiological functions of the MRP family. Drug Resist. Update 3, 289-302.
63. Rivera, E., Valero, V., Esteva, F.J., et al., 2002. Lack of activity of stealth liposomal doxorubicin in the treatment of patients with anthracycline-resistant breast cancer. Cancer Chemother. Pharmacol. 49, 299-302.
64. Romsicki, Y., Sharom, F.J., 1999. The membrane lipid environment modulates drug interactions with the P-glycoprotein multidrug transporter. Biochemistry 38, 6887-6896.
65. Sarris, A.H., Hagemeister, F., Romaguera, J., et al., 2000. Liposomal vincristine in relapsed non-Hodgkin's lymphomas: early results of an ongoing phase II trial. Ann. Oncol. 11, 69-72.
66. Siegal, T., Horowitz, A., Gabizon, A., 1995. Doxorubicin encapsulated in sterically stabilized liposomes for the treatment of a brain tumor model: biodistribution and therapeutic efficacy. J. Neurosurg. 83, 1029-1037.
67. Suzuki, S., Inoue, K., Hongoh, A., Hashimoto, Y., Yamazoe, Y., 1997. Modulation of doxorubicin resistance in a doxorubicin-resistant human leukaemia cell by an immunoliposome targeting transferring receptor. Br. J. Cancer 76, 83-89.
68. Thierry, A.R., Rahman, A., Dritschilo, A., 1993a. Overcoming multidrug resistance in human tumor cells using free and liposomally encapsulated antisense oligodeoxynucleotides. Biochem. Biophys. Res. Commun. 190, 952-960.
69. Thierry, A.R., Vige, D., Coughlin, S.S., Belli, J.A., Dritschilo, A., Rahman, A., 1993b. Modulation of doxorubicin resistance in multidrug-resistant cells by liposomes. FASEB J. 7, 572-579.
70. Treat, J., Damjanov, N., Huang, C., Zrada, S., Rahman, A., 2001. Liposomal-encapsulated chemotherapy: preliminary results of a phase I study of a novel liposomal paclitaxel. Oncology (Huntington) 15, 44-48.
71. van Helvoort, A., Smith, A.J., Sprong, H., Fritzsche, I., Schinkel, A.H., Borst, P., van Meer, G., 1996. MDR1 P-glycoprotein is a lipid translocase of broad specificity, while MDR3 P-glycoprotein specifically translocates phosphatidylcholine. Cell 87, 507-517.
72. West, K.A., Castillo, S., Dennis, P.A., 2002. Activation of the PI3K/Akt pathway and chemotherapeutic agents. Drug Resist. Update 5, 234-248.
73. Westphal, M., Hilt, D.C., Bortey, E., Delavault, P., Olivares, R., Warnke, P.C., Whittle, I.R., Jaaskelainen, J., Ram, Z., 2003. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neurooncology 5, 79-88.
74. Working, P.K., Dayan, A.D., 1996. Pharmacological-toxicological expert report. Caelyx (stealth liposomal doxorubicin HCl). Hum. Exp. Toxicol. 15, 751-785.
75. Zhou, R., Mazurchuk, R., Straubinger, R.M., 2002. Antivasculature effects of doxorubicin-containing liposomes in an intracranial rat brain tumor model. Cancer Res. 62, 2561-2566.
76. Zou, Y., Ling, Y.H., Van, N.T., Priebe, W., Perez-Soler, R., 1994. Antitumor activity of free and liposome-entrapped annamycin, a lipophilic anthracycline antibiotic with non-cross-resistance properties. Cancer Res. 54, 1479-1484.